Viatris Inc. (VTRS) Stock Analysis 2026

HealthcareDrug Manufacturers - Specialty & Generic
$19.20
as of 2026-10-29
+72.0% (52-week)50D MA $16.68  |  200D MA $14.60

BriMind AI Score

Proprietary
27
Weak
Price CAGR
-5.7%
1Y Return
+73.9%
Analyst Upside
+2.8%
Rev Growth
4.9%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$20.42+6.3% potential
Bear Case
$13.76
Bull Case
$25.71
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($20.84) and Wall Street's consensus target ($20.00).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

VTRS Revenue & Profitability Breakdown

This chart shows how VTRS's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$14.74B
Cost of Revenue
-$8.80B
Gross Profit
$5.94B40.3% margin
Operating Expenses
-$4.09B
Operating Income
$1.85B12.6% margin
Tax & Other
-$2.26B
Net Income
-$-410.7M-2.8% margin
Gross Margin
40.3%
Operating Margin
12.6%
Net Margin
-2.8%
EBITDA Margin
29.4%

Key Financial Metrics

Viatris Inc. doesn't carry a meaningful trailing P/E right now, generates $2.68B in free cash flow, runs a debt/equity ratio of 95.53, and converts shareholder equity into profit at a -2.8% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$18.77B
Enterprise Value
$23.68B
P/E (Forward)
6.12
PEG Ratio
1.05
EV / EBITDA
5.62
Price / Sales
0.71
Price / Book
0.66
Revenue
$14.74B
Revenue Growth
4.9%
EBITDA
$4.22B
Gross Margin
40.3%
Operating Margin
12.6%
Net Margin
-2.8%
Return on Equity
-2.8%
Return on Assets
2.7%
Free Cash Flow
$2.68B
Total Cash
$1.00B
Total Debt
$14.46B
Debt / Equity
95.53
Current Ratio
1.58
Quick Ratio
0.82
Beta
0.89
Dividend Yield
2.9%
Payout Ratio
960.0%
Insider Ownership
0.3%
Inst. Ownership
93.4%
Short % Float
3.2%
Book Value / Share
$12.59

Wall Street Analyst Consensus

8 analysts covering Viatris Inc. currently lean toward a Hold rating, with a mean 12-month price target of $18.50 (-3.6% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingHold(8 analysts)
SellStrong Buy
Low Target$8.00-58.3%
Mean Target$18.50-3.6% upside
High Target$14.00+-27.1%

Intrinsic Value Estimates for VTRS

We use 1 valuation model to estimate VTRS's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

DCF Model (10yr)
$47.90
+149.5% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$47.90 – $47.90
Average Estimate
$47.90
Potential Upside
149.5%

Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Technical Price Signals

VTRS is currently in a golden cross pattern, trading above its 50-day average of $16.68 and above its 200-day average of $14.60. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$19.20
50-Day MA
$16.68
▲ Price above
200-Day MA
$14.60
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Further Reading

Research and guides that put VTRS’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Market TheoryStock Market Seasonality: Monthly Returns, 'Sell in May,' and What History SaysMarket TheoryWe Backtested 929 Insider Cluster Buys — The Signal Everyone Trusts Loses to the S&P 500Fundamentals58% of Insider Selling Is Noise — How to Find the Part That MattersMarket TheoryThe Stock-Split Pop Is a Myth: What 39 Real Splits Actually Did

More Healthcare Stock Analysis

In-depth reports on companies operating alongside VTRS — business models, bull and bear cases, and the metrics that matter.

HIMSHims & Hers Health, Inc.Drug Manufacturers - Specialty & GenericPRGOPerrigo Company plcDrug Manufacturers - Specialty & GenericNBIXNeurocrine Biosciences, Inc.Drug Manufacturers - Specialty & GenericNTRANatera, Inc.Diagnostics & ResearchMOHMolina Healthcare, Inc.Healthcare PlansPRMEPrime Medicine, Inc.BiotechnologyALGNAlign Technology, Inc.Medical Instruments & SuppliesINSMInsmed IncorporatedBiotechnology

Unlock the Full VTRS Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis